A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD

Status:
RECRUITING

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

The aim of this Phase 2a study in patients with MDD is to assess safety and tolerability and preliminary antidepressant efficacy.

PHASE2

Gilgamesh Pharmaceuticals